하이텍팜
Financials
Valuation Metrics
하이텍팜's Market Cap is ₩1074B. At end of 2025 it was ₩1278B. Ranked #1240 of 2,421 in KR market (top 51%), #674 of 1,640 on KOSDAQ (top 41%), #139 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 60%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 107.40B KRW | KR#1,240/2,421 Sec#139/231 |
| Revenue | 69.41B KRW | KR#1,626/2,421 Sec#106/231 |
| Net Income | 11.93B KRW | KR#904/2,421 Sec#59/231 |
| Total Assets | 143.70B KRW | KR#1,539/2,421 Sec#116/231 |
| Net Assets | 130.67B KRW | KR#1,228/2,421 Sec#95/231 |
| Employees | 125 | KR#1,468/2,421 Sec#117/231 |
| Value | ||
| P/E | 9.00x | KR#736/2,421 Sec#35/231 |
| P/B | 0.82x | KR#1,288/2,421 Sec#81/231 |
| PEG | 0.70x | KR#724/2,421 Sec#47/231 |
| P/S | 1.55x | KR#1,653/2,421 Sec#95/231 |
| EV/EBITDA | 7.68x | KR#444/2,421 Sec#19/231 |
| FCF Yield | 14.06% | KR#466/2,421 Sec#13/231 |
| Profitability | ||
| ROE | 9.13% | KR#688/2,421 Sec#47/231 |
| ROA | 8.30% | KR#415/2,421 Sec#31/231 |
| Op. Margin | 17.68% | KR#210/2,421 Sec#20/231 |
| Revenue Growth | -7.02% | KR#1,846/2,421 Sec#174/231 |
| Earnings Growth | 12.91% | KR#736/2,421 Sec#49/231 |
| Financial Health | ||
| Debt Ratio | 9.97% | KR#142/2,421 Sec#29/231 |
| Total Debt | 0 KRW | KR—/2,421 Sec—/231 |
| FCF | 15.10B KRW | KR#598/2,421 Sec#31/231 |
| Cash | 13.08B KRW | KR#1,529/2,421 Sec#124/231 |
| Net Debt/EBITDA | -1.07x | KR#372/2,421 Sec#19/231 |
| Dividend | ||
| Div. Yield | 1.47% | KR#1,011/2,421 Sec#54/231 |
| Div. Growth | 50.00% | KR#228/2,421 Sec#9/231 |
| Performance | ||
| 1Y Return | -24.12% | KR#1,379/2,421 Sec#99/231 |
| 1M Return | -17.55% | KR#2,283/2,421 Sec#204/231 |
| From 52W High | -59.60% | KR#1,846/2,421 Sec#141/231 |
| 1Y MDD | -60.16% | KR#1,486/2,421 Sec#118/231 |
| Trading | ||
| Volume | 1,944 shares | KR#2,276/2,421 Sec#213/231 |
| Trading Value | 19.7M KRW | KR#2,144/2,421 Sec#211/231 |
| Foreign Own. | 46.42% | KR#44/2,421 Sec#3/231 |
| Per Share | ||
| EPS | 1,122 KRW | KR#678/2,421 Sec#44/231 |
| BPS | 12,289 KRW | KR#836/2,421 Sec#59/231 |
Company Info
Hitech Pharm, established in 1998 and headquartered in Chungju, Chungcheongbuk-do, is a specialized enterprise for antibiotic raw pharmaceutical ingredients, listed on KOSDAQ in 2010. It primarily produces Carbapenem-class antibiotics, with main products Imipenem and Ertapenem, which are high-priced due to their high antibacterial activity, and largely exported to Europe and Asia. The company possesses Carbapenem-class antibiotic technology achieving higher yields and lower impurities than competitors, fostering its growth in the global market via next-generation production plants.